BiotechTube

Ruxolitinib + Hydroxycarbamide + Interferon-Alpha

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Polycythemia Vera

Conditions

Polycythemia Vera

Trial Timeline

Oct 25, 2019 → Apr 1, 2030

NCT ID
NCT04116502

About Ruxolitinib + Hydroxycarbamide + Interferon-Alpha

Ruxolitinib + Hydroxycarbamide + Interferon-Alpha is a phase 3 stage product being developed by Novartis for Polycythemia Vera. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04116502. Target conditions include Polycythemia Vera.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04116502Phase 3Recruiting

Competing Products

20 competing products in Polycythemia Vera

See all competitors
ProductCompanyStageHype Score
Sapablursen + PlaceboOno PharmaceuticalPhase 3
77
Ruxolitinib + AbemaciclibEli LillyPhase 1
33
BomedemstatMerckPhase 2
52
ruxolitinib tabletsNovartisPhase 3
77
RuxolitinibNovartisPre-clinical
23
RuxolitinibNovartisPhase 3
77
Ruxolitinib + BATNovartisPhase 2
52
HydroxyureaNovartisApproved
85
Best Available Therapy + RuxolitinibNovartisPhase 3
77
Smac Mimetic LCL161NovartisPhase 2
52
PEGASYS + AspirinRochePhase 2
52
RG7388 + PegasysRochePhase 1
33
IdasanutlinRochePhase 2
52
PEGASYS + Hydroxyurea + AspirinRochePhase 3
77
Ropeginterferon alfa-2bPharmaEssentiaPhase 2
51
Pegylated-Proline-Interferon alpha-2b in a Pre-filled PenPharmaEssentiaPhase 3
76
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)PharmaEssentiaPhase 3
76
Ropeginterferon alfa-2bPharmaEssentiaApproved
84
P1101 + Low-dose aspirinPharmaEssentiaPhase 2
51
P1101 (Ropeginterferon alfa-2b)PharmaEssentiaPhase 3
76

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85